NCT02107937View on ClinicalTrials.gov

Phase II Study DCVAC/OvCa Added to First Line Carboplatin and Paclitaxel Newly Diagnosed Epithelial Ovarian Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

136

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

November 30, 2020

Study Completion Date

November 30, 2021

Conditions
Ovarian NeoplasmsOvarian Epithelial Cancer
Interventions
BIOLOGICAL

DCVAC/OvCa with Standard of Care

DCVAC/OvCa is the experimental therapy added on to Carboplatin and Paclitaxel

BIOLOGICAL

DCVAC/OvCa sequentially chemotherapy

DCVAC/OvCa added sequentially after Carboplatin and Paclitaxel

DRUG

Standard of Care

Carboplatin and Paclitaxel is Standard of Care First Line Chemotherapy

Trial Locations (13)

625 00

Brno

656 53

Brno

370 01

České Budějovice

500 05

Hradec Králové

741 01

Nový Jičín

775 20

Olomouc

708 52

Ostrava

304 60

Pilsen

100 34

Prague

128 08

Prague

150 06

Prague

15-276

Bialystok

20-090

Lublin

All Listed Sponsors
lead

SOTIO a.s.

INDUSTRY

NCT02107937 - Phase II Study DCVAC/OvCa Added to First Line Carboplatin and Paclitaxel Newly Diagnosed Epithelial Ovarian Carcinoma | Biotech Hunter | Biotech Hunter